Roche signs up to $2.3 billion deal with Nurix for BTK degrader Bexobrutideg

The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases

Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS

Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology

Roche BTK drug emerges as potential breakthrough in primary progressive MS

Eli Lilly to spotlight groundbreaking BTK inhibitor Jaypirca at ASH 2025

Jaypirca is making waves in the fight against B-cell malignancies

J&J MedTech reports strong one-year results for shockwave peripheral IVL system in DISRUPT BTK II trial

The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year

FDA approves Sanofi’s BTK inhibitor for immune thrombocytopenia

ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life

Philips announces positive research results from its TOBA II BTK clinical trial

First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization

Inmagene receives USFDA IND clearance for a third-generation BTK inhibitor

It is developing the drug candidate to potentially treat immunological diseases

FDA grants accelerated approval to BEQALZI for relapsed mantle cell lymphoma

Roche’s MS drug fenebrutinib delivers striking Phase III results by cutting relapse rates by 58%

The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints